UroToday8d
'Unfavorable Histology’ Classification Aims to Reduce Unnecessary Treatment, Journal Club - Jesse McKenney, Jane Nguyen, & Cornelia Ding
Matthew Cooperberg hosts a discussion with Jesse McKenney and Jane Nguyen about research on prostate cancer grading, presented in a paper proposing a new definition of adverse pathology. Dr. McKenney ...
UroToday11d
Treatment Intensification for High-Risk Biochemically Recurrent M0 HSPC: ‘EMBARK’ing on a Novel Treatment Paradigm
PSA <0.2 ng/mL: Treatment was suspended at week 37 and PSA was monitored with treatment reinitiated if PSA rose again PSA >0.2 ng/mL: Treatment was continued PSA progression (HR 0.07, 95% CI 0.03–0.14 ...
UroToday11d
Treatment Intensification for High-Risk Biochemically Recurrent M0 HSPC: EMBARK in the PSMA PET Era and Ongoing Trials
This drug approval followed the publication of the EMBARK trial, a randomized phase III trial of biochemically recurrent patients who had high-risk disease, defined by a PSA doubling time (PSADT) ≤9 ...
UroToday5d
Comparative analysis of gut microbiota in hormone-sensitive and castration-resistant prostate cancer in Japanese men.
Gut microbiota plays a crucial role in the development and progression of prostate cancer, with previous studies indicating that certain bacterial taxa are more abundant in castration-resistant ...
UroToday5d
Management strategies for radio-recurrent prostate cancer: a comprehensive review.
Radiation- (radio-)recurrent prostate cancer poses a significant challenge in clinical management due to its complexity and varied treatment responses. The recurrence of prostate cancer following ...
UroToday6d
Impact of Tumor Volume and Other Factors on Renal Function After Partial Nephrectomy - Beyond the Abstract
Partial nephrectomy (PN) aims to preserve renal function while achieving tumor control but understanding key predictors of renal outcomes remains essential to refine surgical approaches. In our study, ...
UroToday5d
Multiparametric MRI targeted prostate biopsy: When omit systematic biopsy?
To evaluate the detection rate for prostate cancer (PCa) performing multiparametric magnetic resonance imaging (mpMRI) fusion targeted biopsy (TPBx) combined only with ipsilateral systematic prostate ...
UroToday5d
Bladder sparing management for muscle-invasive bladder cancer after a complete clinical response: ready for prime time?-a narrative review.
A standard of care for muscle-invasive bladder cancer (MIBC) is cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC). Given recent improvements in NAC and the morbidity ...
UroToday5d
MicroRNAs in seminal plasma are able to discern infertile men at increased risk of developing testicular cancer.
Male infertility is a risk factor for the development of testicular germ cell tumors. In this study, we investigated microRNA profiles in seminal plasma to identify potential noninvasive biomarkers ...
UroToday5d
Non-clear cell renal cell carcinoma narrative review: where we are in 2024.
Advances in non-clear cell renal cell carcinoma (RCC) have lagged behind clear cell RCC due to the heterogeneity and relative rarity of the disease. However, more advanced molecular and genetic ...
UroToday5d
Optimal Treatment Strategies for Hormone-sensitive Metastatic Prostate Cancer: Does Local Radiotherapy Play a Role in High-volume Disease?
Optimal treatment strategies for metastatic hormone-sensitive prostate cancer (mHSPC) are evolving with novel multimodal approaches. For well-selected patients, early local radiotherapy can play a ...
UroToday4d
Value-Based Care and Reducing Prescription Drug Costs
Ruchika Talwar hosts Daniel Sentana Lledo to discuss the concept of time toxicity in prostate cancer treatment. Time toxicity measures the amount of time patients spend in the healthcare system and ...